Kailera Therapeutics to Present at ObesityWeek 2026
Canaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
Kailera Therapeutics Q3 EPS $(0.74) Beats $(1.02) Estimate
Kailera Therapeutics to Participate in November Investor Conferences
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028
Kailera Therapeutics to Participate in September Investor Conferences
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win
Kailera weight loss pill trial results: Nausea sinks stock
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
Why Is Kailera Therapeutics Stock Falling Tuesday?
Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.